Walker JL, et al. - In this study with 1,560 women with newly diagnosed advanced ovarian carcinoma followed-up for 84.8 months, researchers assessed how progression-free survival (PFS) was influenced by the administration of two different intraperitoneal (IP) chemotherapy regimens: six cycles of IV paclitaxel 80 mg/m² once per week with intravenous (IV) carboplatin area under the curve 6 (IV carboplatin) vs IV paclitaxel 80 mg/m² once per week with IP carboplatin area under the curve 6 (IP carboplatin) vs once every 3 weeks IV paclitaxel 135 mg/m² over 3 hours day 1, IP cisplatin 75 mg/m² day 2, and IP paclitaxel 60 mg/m² day 8 (IP cisplatin). In cycles 2 to 22, all patients were administered bevacizumab 15 mg/kg IV every 3 weeks. Either IP regimen, when combined with bevacizumab, offered no significantly increased duration of PFS and was better tolerated as compared to IP cisplatin vs the IV carboplatin reference arm.